Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 98
Filtrar
1.
Int J Pediatr Otorhinolaryngol ; 182: 112021, 2024 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-38959761

RESUMO

INTRODUCTION: Postoperative hypocalcaemia is common after thyroidectomy. This study aimed to evaluate whether a standardised post-thyroidectomy protocol using prophylactic calcium and calcitriol reduces hypocalcaemia incidence after total thyroidectomy in children and adolescents. METHODS: A cohort children and adolescents ≤18 years of age undergoing total thyroidectomy between January 2016 and October 2022 in one institution were retrospectively identified and divided into pre-protocol and post-protocol groups. The primary outcome measure was hypocalcaemia (total serum calcium of <2.0 mmol/L; ionised serum calcium of 0.9 mmol/L). Secondary outcome measures were the occurrence of hypercalcaemia (serum Calcium >2.7 mmol/L; ionised calcium >1.31 mmol/L), length of hospitalisation and number of postoperative blood tests. RESULTS: There were 22 patients in each group (mean age 11.8; SD 4.3 years, female 36 %). The rate of hypocalcaemia was significantly higher in the pre-protocol group than the post-protocol group (54 % vs 13.6 %, p = 0.010). Patients in the pre-protocol group had more inpatient blood tests (mean 5.4; SD 3.2) than the post-protocol group (mean 3.3; SD 1.8, p = 0.011), although the total postoperative blood test count was similar between the groups. Six (13.6 %) patients developed hypercalcaemia. The rate of hypercalcaemia was similar between groups (pre-protocol 2, 9.1 %; post-protocol 4, 18.1 %; p = 0.664). Length of hospitalisation was similar between groups. CONCLUSION: Our standardized protocol decreased hypocalcemia and inpatient blood tests after total thyroidectomy in children. Future research should explore if incorporating preoperative calcium and calcitriol treatment, along with intraoperative PTH levels for risk management, can further reduce hypocalcemia rates in paediatric patients.


Assuntos
Calcitriol , Cálcio , Protocolos Clínicos , Hipocalcemia , Complicações Pós-Operatórias , Tireoidectomia , Humanos , Hipocalcemia/prevenção & controle , Hipocalcemia/etiologia , Hipocalcemia/epidemiologia , Hipocalcemia/sangue , Tireoidectomia/efeitos adversos , Tireoidectomia/métodos , Feminino , Criança , Masculino , Adolescente , Estudos Retrospectivos , Cálcio/sangue , Calcitriol/uso terapêutico , Complicações Pós-Operatórias/prevenção & controle , Complicações Pós-Operatórias/epidemiologia , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/diagnóstico , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico
3.
Am J Emerg Med ; 52: 85-91, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-34890894

RESUMO

Hyperkalemia represents a widespread and potentially lethal condition that affects millions of people across their lives. Despite the prevalence and severity of the condition, there are no consensus guidelines on the treatment of hyperkalemia or even a standard definition. Herein, we provide a succinct review of what we believe to be the most significant misconceptions encountered in the emergency care of hyperkalemia, examine current available literature, and discuss practical points on several modalities of hyperkalemia treatment. Additionally, we review the pathophysiology of the electrocardiographic effects of hyperkalemia and how intravenous calcium preparations can antagonize these effects. We conclude each section with recommendations to aid emergency physicians in making safe and efficacious choices for the treatment of acute hyperkalemia.


Assuntos
Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Resinas de Troca de Cátion/uso terapêutico , Hiperpotassemia/tratamento farmacológico , Poliestirenos/uso terapêutico , Lactato de Ringer/uso terapêutico , Cálcio/uso terapêutico , Hormônios e Agentes Reguladores de Cálcio/farmacologia , Resinas de Troca de Cátion/farmacologia , Eletrocardiografia , Serviço Hospitalar de Emergência , Humanos , Hiperpotassemia/diagnóstico , Poliestirenos/farmacologia , Lactato de Ringer/farmacologia
4.
J Endocrinol Invest ; 45(3): 573-582, 2022 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-34637114

RESUMO

PURPOSE: Conventional therapy (calcium and activated vitamin D) does not restore calcium homeostasis in patients with chronic hypoparathyroidism (HypoPT) and is associated with renal complications and reduced quality of life (QoL). The aim of this study was to evaluate in a case-control, cross-sectional study, the rate of renal complications and QoL in two sex- and age-matched cohort of patients with differentiated thyroid cancer with (n = 89) and without (n = 89) chronic post-operative HypoPT (PoHypoPT) and their relationship with the biochemical control of the disease. METHODS: Serum and urinary parameters, renal ultrasound and QoL were assessed by SF-36 and WHO-5 questionnaires. RESULTS: Forty-three (48.3%) PoHypoPT patients reported symptoms of hypocalcemia. Twenty-six (29.2%) patients were at target for all 6 parameters, 46 (51.6%) for 5. The most frequently unmet targets were gender-specific 24-h urinary calcium (44.9%) and serum calcium (37.1%). Serum phosphate, magnesium and 25(OH)D were in the normal range in > 90% of patients. Renal calcifications were found in 26 (29.2%) patients, with no correlation with 24-h urinary calcium. eGFR did not differ between patients and controls. Conversely, patients had a significant higher rate of renal calcifications and a lower SF-36, but not WHO-5, scores. SF-36 scores did not differ between PoHypoPT patients who were, or not, hypocalcemic. CONCLUSIONS: Our study shows that the rate of renal calcifications was higher in patients with PoHypoPT than in those without. This finding, together with the reduced QoL and the presence of hypocalcemic symptoms in about half patients, underscores that the treatment of chronic HypoPT with conventional therapy is suboptimal.


Assuntos
Cálcio , Hipoparatireoidismo , Nefrolitíase , Complicações Pós-Operatórias , Qualidade de Vida , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia , Vitamina D/uso terapêutico , Cálcio/sangue , Cálcio/metabolismo , Cálcio/uso terapêutico , Cálcio/urina , Hormônios e Agentes Reguladores de Cálcio/metabolismo , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Feminino , Humanos , Hipocalcemia/sangue , Hipocalcemia/etiologia , Hipocalcemia/terapia , Hipocalcemia/urina , Hipoparatireoidismo/sangue , Hipoparatireoidismo/complicações , Hipoparatireoidismo/etiologia , Hipoparatireoidismo/psicologia , Masculino , Pessoa de Meia-Idade , Nefrolitíase/sangue , Nefrolitíase/etiologia , Nefrolitíase/psicologia , Nefrolitíase/terapia , Avaliação de Resultados em Cuidados de Saúde , Complicações Pós-Operatórias/sangue , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/psicologia , Complicações Pós-Operatórias/terapia , Inquéritos e Questionários , Neoplasias da Glândula Tireoide/patologia , Tireoidectomia/efeitos adversos , Tireoidectomia/métodos
5.
J Pharm Pract ; 35(6): 874-878, 2022 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-33955282

RESUMO

BACKGROUND: The dramatic increase in the acquisition cost of injectable calcitonin led to creating a pharmacy-driven calcitonin protocol to improve the appropriate use of calcitonin and other treatment modalities for hypercalcemia. OBJECTIVE: This study aimed to characterize the use of calcitonin before and after implementation of a pharmacy-driven calcitonin protocol. METHODS: This was a multi-center, retrospective study of the use of injectable calcitonin in adult hospitalized patients with hypercalcemia. The study included patients treated with calcitonin from October 2014 to September 2016 and from October 2017 to September 2019. The primary outcomes were percentage of patients with a complete response, partial response, and non-responders. The secondary outcomes were time to relapse, duration of partial response, number of doses, and associated costs of calcitonin. RESULTS: Of the 131 patients included in this study, 93 were included in a pre-protocol group and 38 were included in a post-protocol group. The primary outcome of complete response by 3 days was met in 28% of patients in the pre-protocol group and 53% of patients in the post-protocol group (P = 0.007). Calcitonin spending in dollars in the pre-protocol group was $818,956 compared to $224,320 in the post-protocol group; a difference of $594,636. CONCLUSION: Implementation of a pharmacy-driven calcitonin protocol effectively improved calcium levels, reduced inappropriate calcitonin use, and reduced calcitonin spending during a period of 2 fiscal years.


Assuntos
Calcitonina , Hipercalcemia , Farmácia , Adulto , Humanos , Calcitonina/economia , Calcitonina/uso terapêutico , Cálcio/sangue , Hormônios e Agentes Reguladores de Cálcio/genética , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Hipercalcemia/diagnóstico , Hipercalcemia/tratamento farmacológico , Estudos Retrospectivos , Protocolos Clínicos
6.
Biomed Res Int ; 2021: 5504873, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34853790

RESUMO

Chronic kidney disease-mineral bone disorder (CKD-MBD) is the most common complication in CKD patients. Although there is a consensus on treatment guidelines for CKD-MBD, it remains uncertain whether these treatment recommendations reflect actual practice. Therefore, the aim of this study was to investigate the CKD-MBD medication trend in real-world practice. This was a retrospective and observational study using a 12-year period database transformed into a common data model from three tertiary university hospitals. Study populations were subjects initially diagnosed as CKD. The date of diagnosis was designated as the index date. New patients were categorized year to year from 2008 to 2019 with a fixed observation period of 365 days to check the prescription of CKD-MBD medications including calcium-containing phosphate binder, noncalcium-containing phosphate binder, aluminium hydroxide, vitamin D receptor activator (VDRA), and cinacalcet. The numbers of CKD patients in the three hospitals were 7555, 2424, and 5351, respectively. The proportion for patients with CKD-MBD medication prescription decreased yearly regardless of hospital and CKD stage (p for trend < 0.05). The use of aluminium hydroxide disappeared steadily while the use of VDRA increased annually in all settings. Despite these changes in prescription patterns, the mean value for CKD-MBD-related serologic markers was almost within target range. The proportion of the population within the target value was not significantly changed. Irrespective of hospital and CKD stage, similar trends of prescription for CKD-MBD medications were observed in real-world practice. Further research with a distributed network study may be helpful to understand medication trends in CKD-MBD treatment.


Assuntos
Distúrbio Mineral e Ósseo na Doença Renal Crônica/tratamento farmacológico , Adulto , Idoso , Idoso de 80 Anos ou mais , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Distúrbio Mineral e Ósseo na Doença Renal Crônica/etiologia , Cinacalcete/uso terapêutico , Registros Eletrônicos de Saúde , Feminino , Hospitais Universitários , Humanos , Masculino , Pessoa de Meia-Idade , Guias de Prática Clínica como Assunto , Receptores de Calcitriol/agonistas , Insuficiência Renal Crônica/complicações , República da Coreia , Estudos Retrospectivos , Centros de Atenção Terciária
7.
JAMA Otolaryngol Head Neck Surg ; 147(11): 959-965, 2021 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-34617977

RESUMO

Importance: Hypoparathyroidism is one of the most common complications after total or completion thyroidectomy. The reported incidence rate of hypoparathyroidism in the literature is highly variable. Data that provide a better understanding of the magnitude of this postoperative complication are warranted and can provide a stepping stone for further collaborations that aim to reduce complication rates and establish uniform treatment protocols. Objective: To evaluate the incidence of postoperative, persistent hypoparathyroidism after total or completion thyroidectomy in patients who were referred to university hospital centers and assess the association of different definitions with the incidence of hypoparathyroidism. Design, Setting, and Participants: This retrospective multicenter cohort study conducted throughout 2016 in 7 Dutch university hospital centers included 200 patients who were undergoing a total or completion thyroidectomy. Data analysis was conducted in January 2021. Main Outcomes and Measures: We report on the incidence of persistent hypoparathyroidism, defined as the need for active vitamin D with or without calcium supplementation longer than 1 year after surgery. Results: A total of 200 patients (143 women [71.5%]; mean [IQR] age, 49.0 [37.0-62.0] years) were included and 30 patients (15.0%) developed persistent hypoparathyroidism. The incidence of persistent hypoparathyroidism varied between 14.5% (calcium and active vitamin D 1 year postsurgery) to 28.5% (calcium and/or active vitamin D 6 months postsurgery) depending on the definition used. Conclusions and Relevance: In this cohort study, the risk of persistent hypoparathyroidism after total or completion thyroidectomy was 15% in patients who were referred to university hospital centers. The high rate of persistent hypoparathyroidism warrants efforts to reduce this complication rate. There is discrepancy in the definition and treatment of persistent hypoparathyroidism, and use of uniform evidence-based treatment guidelines enables comparison of interventions.


Assuntos
Hipoparatireoidismo/epidemiologia , Hipoparatireoidismo/etiologia , Complicações Pós-Operatórias/epidemiologia , Tireoidectomia , Adulto , Idoso , Cálcio/uso terapêutico , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Feminino , Humanos , Hipoparatireoidismo/diagnóstico , Hipoparatireoidismo/prevenção & controle , Incidência , Masculino , Pessoa de Meia-Idade , Países Baixos , Cuidados Pós-Operatórios/métodos , Complicações Pós-Operatórias/diagnóstico , Complicações Pós-Operatórias/prevenção & controle , Estudos Retrospectivos , Resultado do Tratamento
8.
Medicine (Baltimore) ; 100(42): e27579, 2021 Oct 22.
Artigo em Inglês | MEDLINE | ID: mdl-34678905

RESUMO

RATIONALE: Hypocalciuric hypercalcemia is classified as acquired hypocalciuric hypercalcemia (AHH) and familial hypocalciuric hypercalcemia (FHH). While FHH is inherited as an autosomal dominant trait, AHH is one of the rare acquired diseases and is usually treated with prednisolone. Here, we report a case with relapsing AHH which was well controlled with cinacalcet therapy. PATIENT CONCERN: A 68-year-old Japanese man was referred to our institution because of hypercalcemia. Despite such hypercalcemia, he was almost asymptomatic. DIAGNOSTICS: We diagnosed him as AHH due to the following reason. First, the ratio of calcium (Ca)/creatinine clearance was very low which met the criteria. Second, there was no overt family history of hypercalcemia. Third, his serum Ca level was within the normal range 3 years before. Fourth, despite hypercalcemia, he was almost asymptomatic and had no evidence of primary hyperparathyroidism. INTERVENTIONS: Although it is known that steroid therapy is useful for AHH, optimal treatment remains unknown and cinacalcet therapy is very much limited for the treatment of AHH. In this subject, we introduced cinacalcet therapy for the treatment of relapsing AHH. OUTCOMES: Serum Ca and parathyroid hormone levels were normalized after such therapy with cinacalcet. CONCLUSIONS: We should bear in mind that cinacalcet treatment is effective for the treatment of relapsing AHH.


Assuntos
Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Cinacalcete/uso terapêutico , Hipercalcemia/tratamento farmacológico , Idoso , Creatinina/sangue , Humanos , Masculino
9.
Int Immunopharmacol ; 101(Pt B): 108212, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34656907

RESUMO

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal fibrotic lung disease. However, there are insufficient drugs available for IPF treatment, and the currently used drugs are accompanied by many adverse reactions. Deficiency of vitamin D3 (VD3) in the development of IPF and the potential role of VD3 in the treatment of IPF have attracted increasing attention. In vivo experimental results showed that VD3 could increase the survival rate in bleomycin (BLM)-induced models, relieve lung inflammation, reduce hydroxyproline content, and inhibit collagen deposition and cell apoptosis. We further performed proteomics analysis and screened 251 target proteins that reflect VD3 intervention in BLM-induced animal models. These target proteins were involved in acute inflammation, oxidative stress, antioxidant activity and extracellular matrix binding. Combined with the comprehensive analysis of clinical samples, PSAT1 was screened out as a candidate target related to IPF disease and VD3 treatment. Through further computational analysis, the MAPK signaling pathway was considered to be the most probable candidate pathway for VD3 function targeting IPF. In in vivo experiments, VD3 inhibited BLM-induced expression of PSAT1 and phosphorylation of p38 and ERK1/2 in mouse lung tissue. The experiments of cell proliferation and western blot confirmed that VD3 inhibited the expression of PSAT1 and the activation of the mitogen-activated protein kinase (MAPK) pathway in human pulmonary fibroblasts (HPF). Furthermore, experiments with transfection plasmids overexpressing PSAT1 proved that VD3 could attenuate the proliferation and differentiation of HPF by suppressing the effect of PSAT1 on the MAPK signaling pathway. Finally, we confirmed that vitamin D receptor (VDR) could occupy the PSAT1 promoter to reveal the transcriptional regulation effect of VD3 on PSAT1. In conclusion, VD3 exerted a therapeutic effect on IPF by down-regulating the MAPK signaling pathway via targeting the expression of PSAT1.


Assuntos
Bleomicina/toxicidade , Colecalciferol/uso terapêutico , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Fibrose Pulmonar/induzido quimicamente , Fibrose Pulmonar/tratamento farmacológico , Animais , Antibióticos Antineoplásicos/uso terapêutico , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Fibroblastos/efeitos dos fármacos , Humanos , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Distribuição Aleatória
10.
Sci Rep ; 11(1): 18006, 2021 09 09.
Artigo em Inglês | MEDLINE | ID: mdl-34504264

RESUMO

The objective of this study was to determine the impact of calcium sensing receptor (CASR) A990G genetic polymorphism on parathyroid hormone (PTH) lowering response to cinacalcet treatment when controlling for significant influencing clinical factors. This retrospective study was conducted on 135 Thai hemodialysis (HD) patients with secondary hyperparathyroidism (SHPT). CASR A990G genotypes were determined. The patients were identified as either G carriers (heterozygous or homozygous CASR 990G allele carriers) or noncarriers (homozygous CASR 990A carriers). Tested covariates were baseline PTH level (bPTH), baseline serum phosphate (bPhos), baseline serum calcium (bCa), baseline calcitriol equivalent dose (bCtriol), baseline ergocalciferol dose (bErgo), and age. The ANCOVA showed that intact PTH levels after 12 weeks of cinacalcet treatment (PTHw12) was significantly lower among G carriers compared with noncarriers after controlling for bPTH, bPhos, bCtriol, and bErgo (F(1, 127) = 15.472, p < 0.001), with the adjusted mean difference of 253.7 pg/mL. The logistic regression analysis revealed that the odds of a G carrier achieving 30% PTH reduction after 12-week cinacalcet treatment were 3.968 times greater than the odds for a noncarrier after adjusting for bPhos, bCtriol, and age. In conclusion, the CASR A990G polymorphism significantly influences cinacalcet response in HD patients with SHPT.


Assuntos
Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Cinacalcete/uso terapêutico , Hiperparatireoidismo Secundário/terapia , Polimorfismo de Nucleotídeo Único , Receptores de Detecção de Cálcio/genética , Insuficiência Renal Crônica/terapia , Fatores Etários , Idoso , Alelos , Calcitriol/sangue , Cálcio/sangue , Ergocalciferóis/sangue , Feminino , Expressão Gênica , Genótipo , Heterozigoto , Homozigoto , Humanos , Hiperparatireoidismo Secundário/sangue , Hiperparatireoidismo Secundário/genética , Hiperparatireoidismo Secundário/patologia , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Hormônio Paratireóideo/genética , Fosfatos/sangue , Receptores de Detecção de Cálcio/sangue , Diálise Renal/métodos , Insuficiência Renal Crônica/sangue , Insuficiência Renal Crônica/genética , Insuficiência Renal Crônica/patologia , Estudos Retrospectivos
11.
J Pediatr Endocrinol Metab ; 34(12): 1573-1584, 2021 Dec 20.
Artigo em Inglês | MEDLINE | ID: mdl-34525271

RESUMO

OBJECTIVES: Hereditary hypophosphatemic rickets (HR) is conventionally treated with phosphate and calcitriol. Exploring genotype and phenotypic spectrum of X-linked hypophosphatemic rickets (XLHR), focusing on short-term, long-term, and pubertal impact of conventional treatment was aimed. METHODS: Sixteen patients from 12 unrelated families with HR were analyzed for phosphate regulating endopeptidase homolog X-linked (PHEX) mutation. Initially Sanger sequencing analysis was performed. If PHEX mutation was not detected, multiplex ligation-dependent probe amplification (MLPA) was performed. If molecular defect was detected, first-degree relatives were analyzed. Thirteen patients (81%) and five first-degree relatives with XLHR were evaluated for genotype-phenotype or gender-phenotype correlation. Clinical characteristics and response to conventional treatment were determined retrospectively. RESULTS: Nine different PHEX mutations were identified; four splice-site, three point mutations, and two single exon deletions. Four were novel mutations. Despite conventional treatment, median adult height was lower than median height on admission (-3.8 and -2.3 SDS, respectively), metabolic and radiographic recovery were not achieved, adherence was low (30%). Although mean adult height was better in compliant patients than noncompliants (-2.6 vs. -3.7 SDS, respectively), they were still short. Correlation between phenotype and genotype or gender could not be shown. Median phosphate decreased significantly throughout puberty (p=0.014). Median pubertal height was lower than prepubertal height (-4.4 vs. -3.6 SDS; respectively), pubertal growth spurt was not observed. Among five patients with a follow-up longer than five years, three had nephrocalcinosis (60%), two had hyperparathyroidism (40%), 4/6 (33%) required correction osteotomy. CONCLUSIONS: Conventional treatment appears to have limited effect on metabolic, clinical and radiographic recovery in XLHR. Metabolic control and growth worsened during puberty. Although, long-term adverse effects are yet to be seen, introduction of burosumab as first-line treatment may be an alternative after infancy.


Assuntos
Calcitriol/uso terapêutico , Raquitismo Hipofosfatêmico Familiar/tratamento farmacológico , Transtornos do Crescimento/prevenção & controle , Doenças Metabólicas/prevenção & controle , Mutação , Endopeptidase Neutra Reguladora de Fosfato PHEX/genética , Fosfatos/uso terapêutico , Adulto , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Criança , Pré-Escolar , Raquitismo Hipofosfatêmico Familiar/patologia , Feminino , Seguimentos , Transtornos do Crescimento/patologia , Humanos , Lactente , Recém-Nascido , Masculino , Doenças Metabólicas/patologia , Pessoa de Meia-Idade , Linhagem , Prognóstico , Estudos Retrospectivos , Adulto Jovem
12.
Int J Mol Sci ; 22(15)2021 Jul 30.
Artigo em Inglês | MEDLINE | ID: mdl-34360948

RESUMO

Osteoporosis is one of the major bone disorders that affects both women and men, and causes bone deterioration and bone strength. Bone remodeling maintains bone mass and mineral homeostasis through the balanced action of osteoblasts and osteoclasts, which are responsible for bone formation and bone resorption, respectively. The imbalance in bone remodeling is known to be the main cause of osteoporosis. The imbalance can be the result of the action of various molecules produced by one bone cell that acts on other bone cells and influence cell activity. The understanding of the effect of these molecules on bone can help identify new targets and therapeutics to prevent and treat bone disorders. In this article, we have focused on molecules that are produced by osteoblasts, osteocytes, and osteoclasts and their mechanism of action on these cells. We have also summarized the different pharmacological osteoporosis treatments that target different molecular aspects of these bone cells to minimize osteoporosis.


Assuntos
Conservadores da Densidade Óssea/farmacologia , Hormônios e Agentes Reguladores de Cálcio/farmacologia , Osteoporose/metabolismo , Animais , Conservadores da Densidade Óssea/uso terapêutico , Remodelação Óssea , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Humanos , Osteoclastos/efeitos dos fármacos , Osteoclastos/metabolismo , Osteoporose/tratamento farmacológico , Osteoporose/patologia
15.
J Laryngol Otol ; 135(7): 568-573, 2021 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-34120662

RESUMO

OBJECTIVE: This systematic review aimed to establish the evidence behind the use of pre-operative calcium, vitamin D or both calcium and vitamin D to prevent post-operative hypocalcaemia in patients undergoing thyroidectomy. METHOD: This review included prospective clinical trials on adult human patients that were published in English and which studied the effects of pre-operative supplementation with calcium, vitamin D or both calcium and vitamin D on the rate of post-operative hypocalcaemia following total thyroidectomy. RESULTS: Seven out of the nine trials included reported statistically significantly reduced rates of post-operative laboratory hypocalcaemia (absolute risk reduction, 13-59 per cent) and symptomatic hypocalcaemia (absolute reduction, 11-40 per cent) following pre-operative supplementation. CONCLUSION: Pre-operative treatment with calcium, vitamin D or both calcium and vitamin D reduces the risk of post-operative hypocalcaemia and should be considered in patients undergoing total thyroidectomy.


Assuntos
Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Cálcio/uso terapêutico , Hipocalcemia/prevenção & controle , Complicações Pós-Operatórias/prevenção & controle , Tireoidectomia/métodos , Vitamina D/uso terapêutico , Vitaminas/uso terapêutico , Calcitriol/uso terapêutico , Carbonato de Cálcio/uso terapêutico , Colecalciferol/uso terapêutico , Humanos , Hidroxicolecalciferóis/uso terapêutico , Hipocalcemia/fisiopatologia , Cuidados Pré-Operatórios/métodos
16.
Sci Rep ; 11(1): 10014, 2021 05 11.
Artigo em Inglês | MEDLINE | ID: mdl-33976330

RESUMO

A massively enlarged kidney can impact quality of life of autosomal dominant polycystic kidney disease (ADPKD) patients. A recent in vitro study demonstrated that an allosteric modulator of the calcium sensing receptor decreases adenosine-3',5'-cyclic monophosphate, an important factor for kidney enlargement in ADPKD. Therefore, the present study was performed to determine whether cinacalcet, a calcium sensing receptor agonist, suppresses kidney enlargement in hemodialysis patients with ADPKD. Alteration of total kidney volume together with clinical parameters was retrospectively examined in 12 hemodialysis patients with ADPKD treated at a single institution in Japan. In the non-cinacalcet group with longer hemodialysis duration (n = 5), total kidney volume had an annual increase of 4.19 ± 1.71% during an overall period of 877 ± 494 days. In contrast, the annual rate of increase in total kidney volume in the cinacalcet group (n = 7) was significantly suppressed after cinacalcet treatment, from 3.26 ± 2.87% during a period of 734 ± 352 days before the start of cinacalcet to - 4.71 ± 6.42% during 918 ± 524 days after initiation of treatment (p = 0.047). The present findings showed that cinacalcet could be a novel therapeutic tool for suppression of kidney enlargement in hemodialysis patients with ADPKD.


Assuntos
Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Cinacalcete/uso terapêutico , Falência Renal Crônica/tratamento farmacológico , Rim/efeitos dos fármacos , Rim Policístico Autossômico Dominante/tratamento farmacológico , Idoso , Cálcio/sangue , Hormônios e Agentes Reguladores de Cálcio/farmacologia , Cinacalcete/farmacologia , Feminino , Humanos , Hipertrofia/etiologia , Hipertrofia/prevenção & controle , Rim/patologia , Falência Renal Crônica/sangue , Falência Renal Crônica/complicações , Falência Renal Crônica/patologia , Masculino , Pessoa de Meia-Idade , Tamanho do Órgão/efeitos dos fármacos , Hormônio Paratireóideo/sangue , Fosfatos/sangue , Rim Policístico Autossômico Dominante/sangue , Rim Policístico Autossômico Dominante/complicações , Rim Policístico Autossômico Dominante/patologia , Estudos Retrospectivos
17.
J Clin Pathol ; 74(10): 635-640, 2021 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-33931563

RESUMO

Hypophosphatasia (HPP) is a group of inherited disorders characterised by the impaired mineralisation of bones and/or teeth and low serum alkaline phosphatase (ALP) activity. It is caused by a mutation in the ALPL gene encoding the tissue-non-specific isoenzyme of ALP (TNSALP) resulting in a loss of function. The disease is highly heterogenous in its clinical expression ranging from stillbirth without mineralised bone to the mild form of late adult onset with symptoms and signs such as musculoskeletal pain, arthropathy, lower-extremity fractures, premature loss of teeth or an incidental finding of reduced serum ALP activity. A classification based on the age at diagnosis and the presence or absence of bone symptoms was historically used: perinatal, prenatal benign, infantile, childhood, adult and odontohypophosphatasia. These subtypes are known to have overlapping signs and complications. Three forms of HPP distinguishable by their genetic characteristics have been described: severe, moderate and mild. Severe forms of HPP (perinatal and infantile severe) are recessively inherited, whereas moderate HPP may be dominantly or recessively inherited. The biochemical hallmark of HPP is persistently low serum ALP for age and increase in natural substrates of TNSALP, pyridoxal 5'-phosphate and phosphoethanolamine supported by radiological findings. The diagnosis is confirmed by ALPL sequencing. A multidisciplinary team of experts is essential for the effective management. Calcium restriction is recommended in infants/children to manage hypercalcaemia. A targeted enzyme replacement therapy for HPP has become available and correct diagnosis is crucial to allow early treatment.


Assuntos
Hipofosfatasia/fisiopatologia , Odontogênese , Osteogênese , Desmineralização do Dente/congênito , Fosfatase Alcalina/sangue , Fosfatase Alcalina/genética , Fosfatase Alcalina/uso terapêutico , Cálcio da Dieta/efeitos adversos , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Terapia de Reposição de Enzimas , Predisposição Genética para Doença , Humanos , Hipofosfatasia/epidemiologia , Hipofosfatasia/genética , Hipofosfatasia/terapia , Imunoglobulina G/uso terapêutico , Mutação , Odontogênese/genética , Osteogênese/genética , Fenótipo , Prognóstico , Proteínas Recombinantes de Fusão/uso terapêutico , Desmineralização do Dente/epidemiologia , Desmineralização do Dente/genética , Desmineralização do Dente/fisiopatologia , Desmineralização do Dente/terapia
18.
Rev. cir. (Impr.) ; 73(2): 222-226, abr. 2021.
Artigo em Espanhol | LILACS | ID: biblio-1388801

RESUMO

Resumen El hiperparatiroidismo primario (HPP) se define como un trastorno endocrinológico caracterizado por hipercalcemia y niveles de hormona paratiroidea (PTH) elevados o inadecuadamente normales resultado de la secreción excesiva de PTH de una o más glándulas paratiroides. Con respecto a la causa, en un 85% se debe a un adenoma paratiroideo único y un 95% de los casos son esporádicos, sin un factor etiológico identificable. La presentación clásica en la mayoría de los casos es de forma asintomática, sin embargo, sus síntomas o signos clásicos incluyen los derivados de la afectación renal, donde la nefrolitiasis es la manifestación clínica más frecuente de la afectación ósea y de la hipercalcemia. El diagnóstico es bioquímico, sin necesidad de estudio imagenológico, el cual se realiza únicamente como pruebas localizadoras prequirúrgicas. El tratamiento definitivo es quirúrgico, siendo la paratiroidectomía con abordaje cervical el procedimiento de elección.


Primary hyperparathyroidism (PHP) is defined as an endocrine disorder characterized by hypercalcemia and elevated or inadequately normal parathyroid hormone (PTH) levels resulting from the excessive secretion of PTH from one or more parathyroid glands. The cause of this disorder is due, in 85%, to a single parathyroid adenoma and most cases (95%) are sporadic, without an identifiable etiologic factor. PHP is asymptomatic in most patients, however, classic symptoms or signs include those derived from renal involvement, where nephrolithiasis is the most frequent clinical manifestation, and those derived from bone affectation and hypercalcemia. The diagnosis is biochemical, without the need for an imaging study, which is performed only as pre-surgical locator tests. The definitive treatment is surgical, being the parathyroidectomy with cervical approach the procedure of choice.


Assuntos
Humanos , Hiperparatireoidismo Primário/diagnóstico , Hiperparatireoidismo Primário/etiologia , Hiperparatireoidismo Primário/terapia , Diagnóstico Diferencial , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico
19.
BMC Nephrol ; 22(1): 106, 2021 03 23.
Artigo em Inglês | MEDLINE | ID: mdl-33757437

RESUMO

BACKGROUND: Secondary hyperparathyroidism may lead to increased cardiovascular risk. The use of cinacalcet may improve bone and cardiovascular health with improved parathormone (PTH) and phosphate control. METHODS: This is an open-label prospective randomised controlled trial to compare progression of cardiovascular and chronic kidney disease mineral and bone disorder (CKD-MBD) parameters. Patients were randomised to receive cinacalcet alongside standard therapy or standard therapy alone. Thirty-six haemodialysis patients who had > 90 days on dialysis, iPTH > 300 pg/mL, calcium > 2.1 mmol/L and age 18-75 years were included. Following randomization, all 36 patients underwent an intensive 12-week period of bone disease management aiming for iPTH 150-300 pg/mL. The primary outcome was change in vascular calcification using CT agatston score. Secondary outcomes included pulse wave velocity (PWV), left ventricular mass index (LVMI), carotid intima-media thickness (CIMT), augmentation index (Aix) and bone measurements. The above measurements were obtained at baseline and 12 months. RESULTS: There was no evidence of a group difference in the progression of calcification (median change (IQR) cinacalcet: 488 (0 to1539); standard therapy: 563 (50 to 1214)). In a post hoc analysis combining groups there was a mean (SD) phosphate reduction of 0.3 mmol/L (0.7) and median (IQR) iPTH reduction of 380 pg/mL (- 754, 120). Regression of LVMI and CIMT was seen (P = 0.03 and P = 0.001) and was significantly associated with change of phosphate on multi-factorial analyses. CONCLUSIONS: With a policy of intense CKD-MBD parameter control, no significant benefit in bone and cardiovascular markers was seen with the addition of cinacalcet to standard therapy over one year. Tight control of hyperphosphataemia and secondary hyperparathyroidism may lead to a reduction in LVMI and CIMT but this needs further investigation. Although the sample size was small, meticulous trial supervision resulted in very few protocol deviations with therapy.


Assuntos
Calcinose/prevenção & controle , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Cinacalcete/uso terapêutico , Hiperparatireoidismo Secundário/tratamento farmacológico , Falência Renal Crônica/complicações , Adulto , Hormônios e Agentes Reguladores de Cálcio/efeitos adversos , Espessura Intima-Media Carotídea , Cinacalcete/efeitos adversos , Ventrículos do Coração/anatomia & histologia , Humanos , Hiperparatireoidismo Secundário/etiologia , Falência Renal Crônica/sangue , Falência Renal Crônica/terapia , Pessoa de Meia-Idade , Hormônio Paratireóideo/sangue , Fosfatos/sangue , Estudos Prospectivos , Diálise Renal
20.
Pancreas ; 50(2): 206-213, 2021 02 01.
Artigo em Inglês | MEDLINE | ID: mdl-33565797

RESUMO

OBJECTIVES: Hypercalcemia of malignancy confers a poor prognosis. This systematic review evaluated published cases of hypercalcemia of malignancy presenting with acute pancreatitis (AP), in terms of clinical presentation and outcomes. METHODS: A comprehensive review of PubMed and Embase until March 18, 2020, was conducted. Studies were included if they reported on patients with hypercalcemia of malignancy and AP with attempts to exclude other etiologies of hypercalcemia and AP. Two independent reviewers selected and appraised studies using the Murad tool. RESULTS: Thirty-seven cases were identified. Mean (standard deviation) age was 44.8 (2.46) years. Mean (standard deviation) presenting corrected calcium was 14.5 (0.46) mg/dL. Parathyroid carcinoma (21.6%) and multiple myeloma (21.6%) were the most common malignancies. Cases were classified as severe (37.8%), mild (21.6%), and moderately severe (18.9%), whereas 21.6% did not report severity. Necrotizing pancreatitis developed in 21.6% of cases. Most cases were treated with intravenous hydration and bisphosphonates or calcitonin/calcitonin analogues. Mortality was 32.4% during the same presentation of AP. Among mortality cases, 10 of 12 had severe AP, and 5 of 12 had necrotizing pancreatitis. Degree of hypercalcemia did not influence mortality. CONCLUSION: Acute pancreatitis associated with hypercalcemia of malignancy is rare. One in 3 patients with this presentation may not survive AP.


Assuntos
Hipercalcemia/etiologia , Neoplasias/complicações , Pancreatite/etiologia , Adulto , Idoso , Calcitonina/análogos & derivados , Calcitonina/uso terapêutico , Hormônios e Agentes Reguladores de Cálcio/uso terapêutico , Difosfonatos/uso terapêutico , Feminino , Hidratação , Humanos , Hipercalcemia/diagnóstico , Hipercalcemia/mortalidade , Hipercalcemia/terapia , Masculino , Pessoa de Meia-Idade , Neoplasias/diagnóstico , Neoplasias/mortalidade , Pancreatite/diagnóstico , Pancreatite/mortalidade , Pancreatite/terapia , Pancreatite Necrosante Aguda/etiologia , Medição de Risco , Fatores de Risco , Resultado do Tratamento , Adulto Jovem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA